How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

SA

SWX:Santhera Pharmaceuticals
Get a brief AI stock analysisSaves ~ 15 minutes of your time

SA

Santhera Pharmaceuticals Holding AGSWX Santhera Pharmaceuticals Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XSWX - Six Swiss Exchange

FAIR VALUE

Is SANN undervalued compared to its fair value?

The fair value of SANN stock is hidden CHF. Relative to the market price of 9.25 CHF Santhera Pharmaceuticals Holding AG is hidden.

Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. The company is headquartered in Pratteln, Basel-Landschaft and c...[More about valuation]

Santhera Pharmaceuticals Holding AG Fair Value

Available for registered user
UNLOCK
What is fair value?

Market cap:

0.119 $B

Price:

9.25 CHF

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

7.1

FINANCIALS

Santhera Pharmaceuticals Holding AG financial for reporting period

Income Statement

0.099 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
0.071 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
0.078 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

0.099 B 100%
0.098 B 99%
0.078 B 79%

Balance Sheet

0.11 B
0.06 B


Financial Position Analysis

Assets

0.11 B
Current Assets
0.035 B
Total non-current assets
0.075 B

Total current liabilities
0.044 B
Total non-current liabilities
0.0054 B

Cash Flow Statement

-N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
0.063 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Santhera Pharmaceuticals Holding AG fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
112 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
63 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Santhera Pharmaceuticals Rating

Is SANN attractive for investment based on fundamental analysis?

SANN stock rating is hidden. Santhera Pharmaceuticals Holding AG is a hidden by Eyestock methodology.

Get SANN Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

53

Gross Margin:

97

CFO / Debt ratio:

hidden

Current ratio:

0.4

Debt / Equity ratio:

ROE:

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

SANN.SW analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for SANN.SW to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Santhera Pharmaceuticals Holding AG dividends

SANN.SW dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About SANN.SW stock

About the company Santhera Pharmaceuticals Holding AG

Market cap $B

0.119

Dividend yield

Shares outstanding

85.051371 B

Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. The company is headquartered in Pratteln, Basel-Landschaft and currently employs 39 full-time employees. The company went IPO on 2006-11-03. The firm is involved in the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. The Company’s products include Catena and Raxone brands, which are primarily implemented in the symptomatic treatment of Leber's Hereditary Optic Neuropathy (LHON) diseases. Sathera Pharmaceuticals Holding AG operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.

SANN.SW profile

  • Ticker

    SANN.SW

  • Country

    Switzerland

  • Exchange

    XSWX - Six Swiss Exchange

  • Report currency

    CHF - Swiss franc

  • IPO date

    03 November 2006

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    39

  • City

    Pratteln

  • Address

    Hohenrainstrasse 24

  • Cusip

    H7155R134

Frequently Asked Questions

What sector does Santhera Pharmaceuticals operate in?

Santhera Pharmaceuticals operates in Healthсare sector

What is market cap of Santhera Pharmaceuticals?

Market cap of Santhera Pharmaceuticals is 0.119 USD as of 24 Jul 2024

What is market price of one SANN stock?

Market price of one SANN stock is 9.25 CHF as of 24 Jul 2024

What is Santhera Pharmaceuticals revenue?

According to the recent report Santhera Pharmaceuticals revenue is 99.475

What is Santhera Pharmaceuticals net income?

According to the recent report Santhera Pharmaceuticals net icnome is 78.118

What is Santhera Pharmaceuticals net income growh rate?

Net income growth rate of Santhera Pharmaceuticals is 212